{"id":888,"date":"2026-03-16T15:18:29","date_gmt":"2026-03-16T14:18:29","guid":{"rendered":"https:\/\/studienportal-gyn.de\/preliminary-results-of-the-napistar-1-01-study\/"},"modified":"2026-07-21T11:12:59","modified_gmt":"2026-07-21T09:12:59","slug":"preliminary-results-of-the-napistar-1-01-study","status":"publish","type":"post","link":"https:\/\/studienportal-gyn.de\/en\/preliminary-results-of-the-napistar-1-01-study\/","title":{"rendered":"Preliminary Results of the NAPISTAR 1-01 Study"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"888\" class=\"elementor elementor-888 elementor-667\">\n\t\t\t\t<div class=\"elementor-element elementor-element-ecce295 e-flex e-con-boxed e-con e-parent\" data-id=\"ecce295\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-8467f5b elementor-widget elementor-widget-text-editor\" data-id=\"8467f5b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h2 data-section-id=\"1b6fj6s\" data-start=\"97\" data-end=\"177\">New Targeted Therapy for Platinum-Resistant Ovarian Cancer Under Investigation<\/h2><p data-start=\"179\" data-end=\"569\">At ESGO 2026, the initial results of an early-phase clinical trial of a new drug called <strong data-start=\"247\" data-end=\"258\">TUB-040<\/strong> in patients with <strong data-start=\"280\" data-end=\"316\">platinum-resistant ovarian cancer<\/strong> were presented. This is what is known as an <strong data-start=\"370\" data-end=\"409\">antibody-drug conjugate (ADC)<\/strong> \u2014a targeted therapy that specifically recognizes cancer cells and delivers a potent cytotoxic agent directly to them. <\/p><p data-start=\"179\" data-end=\"569\">TUB-040 is an ADC that targets a protein called <strong>NaPi2b<\/strong> (sodium-dependent phosphate transport protein 2B). NaPi2b is a transporter that regulates phosphate in tissues such as the lungs and intestines and is found on the cell surface at a higher-than-average rate in high-grade serous ovarian cancer and non-small-cell lung cancer. <\/p><h3 data-section-id=\"1eajnas\" data-start=\"571\" data-end=\"603\">What was the study about?<\/h3><p data-start=\"605\" data-end=\"701\">The <strong data-start=\"609\" data-end=\"633\">NAPISTAR 1-01 study<\/strong> is an early <strong data-start=\"649\" data-end=\"667\">Phase 1\/2a study<\/strong> primarily designed to evaluate,<\/p><ul data-start=\"702\" data-end=\"788\"><li data-section-id=\"1grjbtr\" data-start=\"702\" data-end=\"753\"><p data-start=\"704\" data-end=\"753\">how well a new drug is tolerated and<\/p><\/li><li data-section-id=\"d1uytw\" data-start=\"754\" data-end=\"788\"><p data-start=\"756\" data-end=\"788\">What is the appropriate dosage?<\/p><\/li><\/ul><p data-start=\"790\" data-end=\"1093\">A total of <strong data-start=\"807\" data-end=\"826\">67 female patients<\/strong> with platinum-resistant high-grade serous ovarian cancer were treated. Many of them had already received multiple lines of therapy\u2014an average of <strong data-start=\"970\" data-end=\"1001\">four prior treatments<\/strong>\u2014which often included bevacizumab or PARP inhibitors. <\/p><h3 data-section-id=\"16mf3k6\" data-start=\"1095\" data-end=\"1135\">What results were observed?<\/h3><p data-start=\"1137\" data-end=\"1201\">The results are very promising for an early-stage study:<\/p><ul data-start=\"1203\" data-end=\"1495\"><li data-section-id=\"17md2m5\" data-start=\"1272\" data-end=\"1360\"><p data-start=\"1274\" data-end=\"1360\">A confirmed reduction in tumor size was observed in <strong data-start=\"1319\" data-end=\"1344\">50% of the patients<\/strong>.<\/p><\/li><li data-section-id=\"1kux1cm\" data-start=\"1361\" data-end=\"1495\"><p data-start=\"1363\" data-end=\"1495\">Overall, the disease was <strong data-start=\"1399\" data-end=\"1447\">at least stabilized<\/strong> in <strong data-start=\"1399\" data-end=\"1447\">96% of the patients<\/strong>.<\/p><\/li><\/ul><p data-start=\"1497\" data-end=\"1731\">In addition, many of the observed treatment responses were still ongoing at the time of the evaluation, so the final results are still pending.<\/p><h3 data-section-id=\"1df88k4\" data-start=\"1733\" data-end=\"1751\">Side Effects<\/h3><p data-start=\"1753\" data-end=\"1804\">Overall, the treatment was <strong data-start=\"1784\" data-end=\"1801\">well tolerated<\/strong>. The most common side effects included nausea, fatigue, and changes in blood test results. Serious side effects were relatively rare. It is also important to note that <strong data-start=\"1973\" data-end=\"2055\">no serious problems such as pneumonia, nerve damage, or eye problems<\/strong> were observed.   <\/p><h3 data-section-id=\"7ecdqd\" data-start=\"2116\" data-end=\"2154\">What does this mean for female patients?<\/h3><p data-start=\"2156\" data-end=\"2383\">The results show that <strong data-start=\"2184\" data-end=\"2229\">TUB-040<\/strong> could be <strong data-start=\"2184\" data-end=\"2229\">a potential new treatment option<\/strong> for patients with platinum-resistant ovarian cancer, especially for those in whom multiple prior treatments have failed.<\/p><p data-start=\"2385\" data-end=\"2596\">However, this is still an <strong data-start=\"2425\" data-end=\"2449\">early Phase 1\/2 trial<\/strong>. The drug must therefore be tested in <strong data-start=\"2487\" data-end=\"2507\">larger studies<\/strong> before a decision can be made on whether it will be used routinely in the future. <\/p><p data-start=\"2385\" data-end=\"2596\">Source: <a href=\"https:\/\/www.international-journal-of-gynecological-cancer.com\/article\/S1048-891X(25)02202-9\/fulltext\" target=\"_blank\" rel=\"noopener\">Publication<\/a> (the article is in English)<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>New Targeted Therapy for Platinum-Resistant Ovarian Cancer Under Investigation At ESGO 2026, the initial results of an early-phase clinical trial of a new drug called TUB-040 in patients with platinum-resistant ovarian cancer were presented. This is what is known as an antibody-drug conjugate (ADC) \u2014a targeted therapy that specifically recognizes cancer cells and delivers a [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":547,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[53,54],"tags":[],"class_list":["post-888","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-studies"],"acf":[],"_links":{"self":[{"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/posts\/888","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/comments?post=888"}],"version-history":[{"count":1,"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/posts\/888\/revisions"}],"predecessor-version":[{"id":890,"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/posts\/888\/revisions\/890"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/media\/547"}],"wp:attachment":[{"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/media?parent=888"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/categories?post=888"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/tags?post=888"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}